use the module with augmented reality (Mini-Docs) on tablet during TB injection
OtherProvision of a tablet with a module using augmented reality (Mini-Docs) during TB injections in addition to the commonly used drug technology
NCT Number: NCT02596412
Children with cerebral palsy may benefit from treatment with botulinum toxin injections to decrease spasticity for improve function and quality of life. These injections cause repeated pain throughout childhood and may be the cause of post-traumatic stress despite drug and non-drug pain management. The Mini-Docs project of the French Red Cross has a module based on a digital device with augmented reality. Distracting the child, the use of this module on a tablet would reduce pain felt during botulinum toxin injections.
Looking for future studies?
Notify Me3 year–8 year
All sexes
Interventional
Not applicable
Centre Médecine Physique et de Réadaptation pour Enfants de Bois-Larris - Croix-Rouge française, Lamorlaye, France
Objective: To evaluate the effect of the use of a module with augmented reality (Mini-Docs) on pain during botulinum toxin injections in children with cerebral palsy aged from 3 to 8 years
Method: Randomized controlled trial comparing a group of children receiving the module with augmented reality of the Mini-Docs and drug pain management (nitrous oxide and medications), with a group of children receiving the usual care of pain management that combines drug pain management (nitrous oxide and medications) and distraction techniques. The device with the augmented reality module allows the child to add virtual content to the real images of the care. The pain will be assessed for each child 10 minutes after the injections, using a self-assessment scale (the Faces Pain Scale - Revised) or a heteroevaluation scale (the Face Legs Activity Cry Consolability scale given by the nurse). The study will be conducted in two centers of physical medicine and pediatric rehabilitation of the French Red Cross (Paris and Lyon).
Expected Results:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Provision of a tablet with a module using augmented reality (Mini-Docs) during TB injections in addition to the commonly used drug technology
Time frame: Assessment 10 minutes after TB injection
Standardized pain scores will be calculated on a scale from 0 to 10 points using validated tools adapted to the age of the child: the Faces Pain Scale - Revised (FPS-R) and the Face Legs Activity Cry Consolability (FLACC). With each scale, patient scoring ≥ 4 is defined as painful.
Time frame: Assessment up to 1h before TB injection and up to 1h after TB injection
measured by the Modified Yale Preoperative Anxiety Scale Questionnaire (m-Ypas), completed by the parents accompanying the child before and after TB injections
Time frame: Assessment up to 1h before TB injection and up to 1h after TB injection
It will be measured by the Stait Trait Anxiety Inventory (STAI) questionnaire before and after TB injections.
Time frame: 7 days after TB injection
Mini-Docs acceptability will be assessed by telephone interview with the parents of the intervention group 7 days after the of TB injection
Hospices Civils de Lyon
Other
MINIDOCS : Contribution of Augmented Reality to Reduce Pain During of Botulinum Toxin Injections in Cerebral-palsied Children. A Randomized Controlled Trial
Acronym: MINIDOCS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06485830
Brain Damage, Chronic, Brain Diseases
Córdoba, Cordoba, Spain
View Trial DetailsNCT02364856
Brain Damage, Chronic, Brain Diseases
Lille, France
View Trial DetailsNCT05839795
Behavior, Behavioral Symptoms
Kirikkale, Turkey (Türkiye)
View Trial DetailsNCT04219020
Brain Damage, Chronic, Brain Diseases
Saint Paul, Minnesota, United States
View Trial Details